← Back to Home

AbbVie Partners with Iambic on AI Small-Molecule Drug Development; Telix Plans ITM Acquisition to Integrate Isotope Supply

Two deals announced in September direct resources toward drug design and radiopharmaceutical manufacturing, respectively. The former still requires experimental and clinical validation, while the latter ties part of the acquisition price to a drug candidate’s approval and sales results.

By SURL BioNews

Finding a promising molecule is just one step in drug development; selecting candidates worth investing in and ensuring reliable manufacturing also affect the chances of treatments reaching patients. On September 21, 2026, AbbVie and Iambic announced an AI drug discovery collaboration, while Telix announced an agreement to acquire ITM, a radioisotope and drug development company, committing resources to these two stages, respectively.

The multiyear collaboration between AbbVie and Iambic will focus on small-molecule therapies in immunology, neuroscience, and oncology. The collaboration will use Iambic’s Enchant v3 multimodal Transformer model to integrate different types of biomedical data from the drug discovery process, helping researchers assess multiple molecular properties simultaneously and test design hypotheses in parallel. The tool’s specific purpose is to help teams decide which molecules warrant further synthesis and experimentation.

According to AbbVie’s announcement, Enchant v3’s training covers more than 6,000 molecular properties; this figure is neither a patient count nor a measure of the scale of clinical validation. The announcement did not provide specific targets for this collaboration, the number of training data records, or independent comparative results, so it remains impossible to quantify how much it could shorten development timelines or improve success rates. Iambic will receive an upfront payment and may also receive milestone payments and tiered royalties on sales based on results. Financial terms were not disclosed.

The other deal shifts the focus to radiopharmaceutical supply and manufacturing. Telix agreed to acquire all shares in ITM for initial consideration of US$1.65 billion on a cash-free, debt-free basis, with approximately US$1.25 billion expected to be paid in Telix shares. Up to an additional US$700 million in contingent consideration depends on ITM-11 achieving specified regulatory approval and sales milestones and cannot be treated as a confirmed payment.

The core resources ITM brings include lutetium-177 manufacturing capacity and ITM-11, a radiopharmaceutical candidate for gastroenteropancreatic neuroendocrine tumors. This lutetium-177-edotreotide drug targets somatostatin receptors and has completed the Phase III COMPETE trial. However, a presentation Telix filed with the U.S. Securities and Exchange Commission explicitly stated that, as of the announcement, ITM-11 had not received marketing authorization in any jurisdiction; completing a Phase III trial still does not mean approval for use.

The transaction documents indicate that Telix aims to connect isotope production, drug development, and commercial supply more closely, and identifies the expansion of actinium-225 capacity, followed by terbium-161 capacity, as long-term growth opportunities. These plans remain subject to execution and regulatory uncertainties. At signing, the company expected the transaction to close before the end of fiscal year 2026, subject to Telix shareholder approval, regulatory approvals, and other closing conditions.

The two deals set different validation hurdles: the AI collaboration needs experimental and clinical results to demonstrate more accurate molecule selection, while radiopharmaceutical integration must translate manufacturing capacity into reliable supply and advance the regulatory review of drug candidates. The combination of funding and technology enables this work to begin; whether patients will benefit still depends on subsequent evidence.

References

  1. Pharmaceutical Executive
  2. AbbVie
  3. Telix Pharmaceuticals
  4. Telix Pharmaceuticals via U.S. Securities and Exchange Commission